Compare Stocks → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADVMNASDAQ:CLLSNASDAQ:DBVTNASDAQ:MGTXNASDAQ:VCEL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADVMAdverum Biotechnologies$9.76-4.2%$15.83$7.10▼$29.70$202.52M0.84243,594 shs383,120 shsCLLSCellectis$2.51+0.4%$2.64$0.96▼$3.77$139.51M3.1240,224 shs948 shsDBVTDBV Technologies$0.69-0.1%$0.78$0.65▼$2.37$133.08M0.7549,772 shs8,995 shsMGTXMeiraGTx$4.71-3.1%$5.88$3.49▼$8.35$302.46M1.29153,108 shs30,788 shsVCELVericel$44.89-2.6%$47.52$29.70▼$53.05$2.17B1.71538,517 shs44,966 shs7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADVMAdverum Biotechnologies-7.36%-10.22%-31.84%+13.85%+23.95%CLLSCellectis-4.57%+1.63%-3.10%-10.39%+28.87%DBVTDBV Technologies-5.74%-2.21%-13.64%-26.66%-56.54%MGTXMeiraGTx-1.42%-7.43%-24.18%-27.68%-8.13%VCELVericel-0.67%-0.32%-3.82%+8.24%+55.20%“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)See this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)Get the free details now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADVMAdverum Biotechnologies3.9657 of 5 stars3.52.00.04.82.62.50.0CLLSCellectis2.0614 of 5 stars3.52.00.00.00.62.51.3DBVTDBV Technologies2.1732 of 5 stars3.23.00.00.00.03.31.3MGTXMeiraGTx3.7299 of 5 stars3.53.00.04.80.01.70.6VCELVericel0.4308 of 5 stars1.50.00.00.02.70.81.9Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADVMAdverum Biotechnologies3.00Buy$34.67255.19% UpsideCLLSCellectis3.00Buy$8.50238.65% UpsideDBVTDBV Technologies2.33Hold$5.00624.64% UpsideMGTXMeiraGTx3.00Buy$25.67444.94% UpsideVCELVericel3.00Buy$46.403.36% UpsideCurrent Analyst RatingsLatest DBVT, MGTX, ADVM, VCEL, and CLLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.003/19/2024ADVMAdverum BiotechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.003/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.003/1/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$51.00 ➝ $54.003/1/2024VCELVericelHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$46.00 ➝ $53.002/21/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.002/6/2024ADVMAdverum BiotechnologiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $40.001/25/2024VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$39.00 ➝ $51.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADVMAdverum Biotechnologies$3.60M56.26N/AN/A$8.26 per share1.18CLLSCellectis$25.73M5.42N/AN/A$2.76 per share0.91DBVTDBV Technologies$15.73M8.46N/AN/A$0.73 per share0.95MGTXMeiraGTx$14.02M21.58N/AN/A$2.17 per share2.17VCELVericel$197.52M11.00$0.02 per share2,634.21$4.73 per share9.49Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADVMAdverum Biotechnologies-$117.17M-$11.60N/AN/AN/AN/A-98.65%-52.85%5/9/2024 (Estimated)CLLSCellectis-$106.14M-$1.67N/AN/AN/A-346.65%-73.03%-32.22%5/2/2024 (Estimated)DBVTDBV Technologies-$72.73M-$0.39N/AN/AN/A-461.32%-46.33%-35.32%5/2/2024 (Estimated)MGTXMeiraGTx-$84.03M-$1.47N/A5.23N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)VCELVericel-$3.18M-$0.09N/A89.78N/A-1.61%-1.55%-1.02%5/8/2024 (Confirmed)Latest DBVT, MGTX, ADVM, VCEL, and CLLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2024N/AVCELVericel-$0.11N/A+$0.11N/AN/AN/A3/18/2024Q4 2023ADVMAdverum Biotechnologies-$2.80-$2.30+$0.50-$2.30N/AN/A3/14/2024Q4 2023MGTXMeiraGTx-$0.46-$0.47-$0.01-$1.36$10.13 million$2.04 million3/7/2024Q4 2023DBVTDBV Technologies-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million 2/29/2024Q4 2023VCELVericel$0.18$0.26+$0.08$0.26$64.28 million$65.00 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADVMAdverum BiotechnologiesN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADVMAdverum BiotechnologiesN/A4.134.13CLLSCellectis0.572.202.20DBVTDBV TechnologiesN/A4.264.26MGTXMeiraGTx0.622.382.38VCELVericelN/A4.494.21OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADVMAdverum Biotechnologies48.17%CLLSCellectis63.90%DBVTDBV Technologies71.74%MGTXMeiraGTx67.48%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipADVMAdverum Biotechnologies5.30%CLLSCellectis16.41%DBVTDBV Technologies0.71%MGTXMeiraGTx9.70%VCELVericel5.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADVMAdverum Biotechnologies12120.75 million19.66 millionOptionableCLLSCellectis23155.58 million46.46 millionOptionableDBVTDBV Technologies104192.87 million191.50 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionableVCELVericel31448.38 million45.86 millionOptionableDBVT, MGTX, ADVM, VCEL, and CLLS HeadlinesSourceHeadlineNew York State Common Retirement Fund Sells 30,717 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 25 at 8:29 AMVericel to Report First-Quarter 2024 Financial Results on May 8, 2024globenewswire.com - April 24 at 8:30 AMFederated Hermes Inc. Has $19.96 Million Stock Position in Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 22 at 5:56 AMVericel Corporation (VCEL) stock historical prices & data – Yahoo Financenz.finance.yahoo.com - April 21 at 11:52 PMDominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) Stockinsidertrades.com - April 21 at 4:32 AMVericel Co. (NASDAQ:VCEL) CEO Sells $780,325.00 in Stockinsidertrades.com - April 20 at 7:12 AMVericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo Sells 17,500 Sharesmarketbeat.com - April 19 at 6:44 PMKnights of Columbus Asset Advisors LLC Purchases 112,169 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 19 at 1:38 PMVericel Corpmoney.usnews.com - April 17 at 9:10 PMMutual of America Capital Management LLC Sells 21,706 Shares of Vericel Co. (NASDAQ:VCEL)marketbeat.com - April 15 at 5:51 AMVericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking Evenfinance.yahoo.com - April 13 at 1:24 PMVericel Co. (NASDAQ:VCEL) Sees Large Increase in Short Interestmarketbeat.com - April 12 at 10:31 AMVericel Co. (NASDAQ:VCEL) Shares Acquired by Conestoga Capital Advisors LLCmarketbeat.com - April 10 at 3:55 PMVericel Co. (NASDAQ:VCEL) Given Average Rating of "Buy" by Brokeragesmarketbeat.com - April 8 at 4:13 AMCommit To Buy Vericel At $25, Earn 9% Annualized Using Optionsnasdaq.com - April 7 at 10:47 PMVericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 3,278 Sharesinsidertrades.com - March 30 at 7:35 AMVericel Co. (NASDAQ:VCEL) Stock Holdings Decreased by SG Americas Securities LLCmarketbeat.com - March 30 at 4:17 AMVericel (NASDAQ:VCEL) Sets New 1-Year High at $51.40marketbeat.com - March 27 at 11:23 AMAnalyst Scoreboard: 5 Ratings For Vericelmarkets.businessinsider.com - March 27 at 1:54 AMTruist Financial Reaffirms "Buy" Rating for Vericel (NASDAQ:VCEL)marketbeat.com - March 26 at 9:35 AMVericel Co. (NASDAQ:VCEL) COO Sells $352,046.54 in Stockinsidertrades.com - March 14 at 9:39 AMVericel Co. (NASDAQ:VCEL) SVP Sells $367,852.95 in Stockinsidertrades.com - March 12 at 4:46 AMVCEL Oct 2024 50.000 callca.finance.yahoo.com - March 3 at 7:05 PMUS$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These Resultsfinance.yahoo.com - March 3 at 9:03 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAdverum BiotechnologiesNASDAQ:ADVMAdverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.CellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.DBV TechnologiesNASDAQ:DBVTDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.VericelNASDAQ:VCELVericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.